PDCD1 and skin basal cell carcinoma: Using the datasets from Yost et al., the MAIT signature performed well in BCC and SCC tumors both before and after anti-PD-1 therapy, suggesting that it is reasonably robust to changes in biological state (Supplementary Figures 5A,B).